L-dopa was recently reported to suppress cellular growth via down-regulation of prolactin-mediated JAK2/STAT5A in breast cancer cells 50, and carbidopa was reported to be an aryl hydrocarbon receptor agonist and to suppress the growth of pancreatic cancer 51. Here, PRL is linked to familial pancreatic carcinoma.